Dr. Michael Atkins, a medical oncologist who specializes in melanoma, talks about the results of the DREAMseq trial and how the information will hopefully extend life for more patients with advanced melanoma
This trial is for patients who have cancer cells still in the blood or bone marrow after approximately one year of lenalidomide maintenance therapy following a stem cell transplant